Klümper Niklas, Eckstein Markus, Kunath Frank, Heidegger Isabel, Becker Christoph, Rausch Steffen
Klinik und Poliklinik für Urologie und Kinderurologie, Universitätsklinikum Bonn (UKB), Bonn, Deutschland.
Institut für Experimentelle Onkologie, Universitätsklinikum Bonn (UKB), Bonn, Deutschland.
Urologie. 2023 Nov;62(11):1193-1199. doi: 10.1007/s00120-023-02175-5. Epub 2023 Sep 1.
This compact review article highlights the background and importance of nectins in cancer therapy, focusing specifically on the antibody-drug conjugate enfortumab vedotin (EV) as a targeted treatment option for metastatic urothelial carcinoma. The evolving understanding of nectin-4 expression and its impact on EV therapy underscores the need for personalized approaches to ensure optimal patient outcomes. Further investigation into biomarker-guided therapies and prospective clinical trials are critical to refining patient selection and treatment strategies.
这篇综述文章重点介绍了NECTIN在癌症治疗中的背景和重要性，特别关注抗体药物偶联物enfortumab vedotin（EV）作为转移性尿路上皮癌的靶向治疗选择。对NECTIN-4表达及其对EV治疗影响的不断深入理解强调了采用个性化方法以确保患者获得最佳治疗效果的必要性。进一步研究生物标志物引导的疗法和前瞻性临床试验对于优化患者选择和治疗策略至关重要。
